Disease-A-Month
Volume 55, Issue 3 , Pages 121-192 , March 2009

Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease

References 

  1. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. N Engl J Med. 1993;328:246–252
  2. Pearson NI, Chesney MA. The CAM education program of the National Center for Complementary and Alternative Medicine: an overview. Acad Med. 2007;82:921–926
  3. Gaylord SA, Mann JD. Rationales for CAM education in health professions training programs. Acad Med. 2007;82:927–933
  4. Saydah SH, Eberhardt MS. Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. J Altern Complement Med. 2006;12(8):805–812
  5. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98:673–680
  6. Barraco D, Valencia G, Riba AL, et al. Complementary and alternative medicine (CAM) use patterns and disclosure to physicians in acute coronary syndromes patients. Complement Ther Med. 2005;13(1):34–40
  7. Krasuski RA, Michaelis K, Eckart RE. The cardiovascular patient's perceptions of complementary and alternative medicine. Clin Cardiol. 2006;29:161–164
  8. Honda K, Jacobson JS. Use of complementary and alternative medicine among United States adults: the influences of personality, coping strategies, and social support. Prev Med. 2005;40(1):46–53
  9. Krucoff MW, Liebowitz R, Vogel JHK, et al. Complementary and alternative medicine therapy in cardiovascular care. In:  Fuster V,  Alexander RW,  O'Rourke RA, et al. editor. Hurst's The Heart. 11th ed.. New York, NY: McGraw Hill; 2004;p. 2463–2472
  10. Frishman WH, Lee W-N, Glasser SP, et al. The placebo effect in cardiovascular disease. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics. 2nd ed.. New York, NY: McGraw Hill; 2003;p. 15–25
  11. Walach H, Jonas WB. Placebo research: the evidence base for harnessing self-healing capacities. J Alt Comp Med. 2004;10(suppl 1):1;S103-12.
  12. Matter-Walstra K, Schoeni-Affolter F, Widmer M, et al. Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. J Eval Clin Pract. 2008;14:75–82
  13. Miller KL, Liebowitz RS, Newby LK. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J. 2004;147:401–411
  14. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139:56–70
  15. Frishman WH, Sinatra ST, Kruger N. Nutriceuticals and cardiovascular illness. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 58–85
  16. Ridinger MHT. Nutraceuticals: miracle or meme?. Nature. 2007;82:352–356
  17. Frishman WH. Nutriceuticals as treatments for cardiovascular disease. (editorial) Heart Dis. 1999;1:51
  18. Riccioni G, Mancini B, Di Ilio E, et al. Protective effect of lycopene in cardiovascular disease. Eur Rev Med Pharmacol Sci. 2008;12:183–190
  19. Frishman WH, Kruger NA, Nayak DU, et al. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free-radical scavengers in the prevention and treatment of cardiovascular disease. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics. 2nd ed.. New York, NY: McGraw Hill; 2003;p. 407–427
  20. Pryor WA. Vitamin E and heart tissue: basic science to clinical intervention trials. Free Radic Biol Med. 2000;28:141–164
  21. Rapola JM, Virtamo J, Ripatti S, et al. Randomized trial of alpha-tocopherol and beta carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–1720
  22. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet. 1996;347:781–786
  23. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet. 1999;354:447–455
  25. Jialal I, Traber M, Deveraj S. Is there a vitamin E paradox?. Curr Opin Lipidol. 2001;12:49–53
  26. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet. 2003;361:2017–2023
  27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplement in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:23–33
  28. Rasool AH, Rahman AR, Yuen KH, et al. Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. Arch Pharm Res. 2008;31(9):1212–1217
  29. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation of vitamin E supplementation on the occurrence of venous thromboembolism (Report from the Women's Health Study). Circulation. 2007;116:1497–1503
  30. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2008;168(7):773
  31. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men (The Physicians' Health Study II randomized controlled trial). JAMA. 2008;300:2123–2133
  32. Hatzigeorgiou C, Taylor AJ, Feuerstein IM, et al. Antioxidant vitamin intake and subclinical coronary atherosclerosis. Prevent Cardiol. 2006;9:75–81
  33. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness: the ARIC Study. Circulation. 1995;92:2142–2150
  34. Osganian SK, Stampfer MJ, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003;42:246–252
  35. Kaw KT, Bingham S, Welch A, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk Prospective Study: a prospective population study. Lancet. 2001;357:657–663
  36. Mikirova NA, Thomas IE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med. 2008;6:50
  37. Kruger NA, Frishman WH, Hussain J. Fish oils, the B vitamins and folic acid as cardiovascular protective agents. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics. 2nd ed.. New York, NY: McGraw Hill; 2003;p. 381–405
  38. Chan P, Huang TY, Chen YJ, et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol. 1998;38:1151–1154
  39. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111–128
  40. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid artery disease. N Engl J Med. 1995;332:286–291
  41. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among post-menopausal women. JAMA. 1999;281:1817–1821
  42. Hankey GJ, Eikeboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407–413
  43. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention (Wrong again?). JAMA. 2008;299:2086–2087
  44. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  45. Spence JD, Bang H, Chambless LE, et al. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke. 2005;36:2404–2409
  46. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146:761–767
  47. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  48. Bleie O, Semb AG, Grundt H, et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med. 2007;262:244–253
  49. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–2036
  50. Jamison RL, Hartigan P, Kaulman JS, et al. Veterans Affairs Site Investigators Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease (A randomized controlled trial). JAMA. 2007;298:1163–1170
  51. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B–26B
  52. Meyers CD, Carr MC, Park S, et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139:996–1002
  53. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82:29U–34U
  54. Goldberg A, Alagona P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85:1100–1105
  55. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan) dose escalation study. Am J Cardiol. 1998;82:35U–38U
  56. Cefali EA, Simmons PD, Stanek EJ, et al. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther. 2006;44(12):633–640
  57. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101(5):625–630
  58. Lai E, Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Therap. 2007;81:849–857
  59. Somjen D, Weisman Y, Kohen F, et al. 25-Hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111:1666–1671
  60. Merke J, Milde P, Lewicka S, et al. Identification and regulation of 1,25-hydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest. 1989;83:1903–1915
  61. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353–373
  62. Moats C, Rimm EB. Vitamin intake and risk of coronary disease: observation versus intervention. Curr Atheroscler Rep. 2007;9:508–514
  63. Wallis DE, Penckofer S, Sizemore GW. The “Sunshine Deficit” and cardiovascular disease. Circulation. 2008;118:1476–1485
  64. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340–1349
  65. Giovannucci E, Liu Y, Hollis BW, et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–1180
  66. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–654
  67. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41–46
  68. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–511
  69. Pilz S, Dobnig H, Fischer JE, et al. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke. 2008;39:2611–2613
  70. Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93:3927–3935
  71. Fleck A. Latitude and ischaemic heart disease. Lancet. 1989;1:613
  72. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care. 2008;11:752–757
  73. Erkkila AT, Booth SL. Vitamin K intake and atherosclerosis. Curr Opin Lipidol. 2008;19:39–42
  74. Greenberg ER, Baron JA, Karagas MR, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA. 1996;275:699–703
  75. Gey FK, Puska P. Plasma vitamin E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci. 1989;570:268–282
  76. Kardinaal AF, Kok FJ, Ringstad J, et al. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Lancet. 1993;342:1379–1384
  77. Gitenay D, Lyan B, Rambeau M, et al. Comparison of lycopene and tomato effects on biomarkers of oxidative stress in vitamin E deficient rats. Eur J Nat. 2008;46(8):468–475
  78. Ullah MF, Khan MW. Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pac J Cancer Prev. 2008;9(2):187–196
  79. Maxwell S, Cruickshank A, Thorpe D. Red wind and antioxidant activity in serum. Lancet. 1994;344:193–194
  80. Hertog MC, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007–1011
  81. Duffy SJ, Keaney JF, Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001;104:151–156
  82. Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr. 2008;138(9):1602–1608
  83. Clinical Trial: Trial to assess bioavailability of flavonoids and phenolic acids. www.clinicaltrials.gov/ct
  84. Rimm EB, Katan MB, Ascherio A, et al. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med. 1996;125:384–389
  85. Clinical Trial: Trial to assess concord grape juice. www.clinicaltrials.gov/ct
  86. Frishman WH, DelVecchio A, Sanal S, et al. Cardiovascular manifestations of substance abuse (Part 2: Alcohol, amphetamines, heroin, cannabis, caffeine). Heart Dis. 2003;5:253–271
  87. Mehrinfar R, Frishman WH. Flavanol-rich cocoa (A cardioprotective nutriceutical). Cardiol Rev. 2008;16:109–115
  88. Hollenberg NK, Fisher NDL. Is it the dark in dark chocolate?. Circulation. 2007;116:2360–2362
  89. Cohen DL, Townsend RR. Cocoa ingestion and hypertension—another cup please?. J Clin Hypertens. 2007;9:647–648
  90. Flammer AJ, Hermann F, Sudano I, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation. 2007;116:2376–2382
  91. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich). 2008;10(7 suppl 2):3–11
  92. Cojocaru IM, Cojocaru M, Burcin C, et al. Serum magnesium in patients with acute ischemic stroke. Rom J Intern Med. 2008;45(3):269–273
  93. McLean RM. Magnesium and its therapeutic uses: a review. Am J Med. 1994;96:63–76
  94. Shechter M. Oral magnesium in coronary artery disease: fresh insight on thrombus inhibition. Magn Rep. 1999;1–4
  95. Ho KM. Intravenous magnesium for cardiac arrhythmias: jack of all trades. Magnes Res. 2008;21(1):65–68
  96. Shechter M, Merz CN, Paul-Labrador M, et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999;84:152–156
  97. Lichodziejewska B, Klos J, Rezler J, et al. Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation. Am J Cardiol. 1997;79:768–772
  98. Preuss HG, Wallerstedr' D, Talpur N, et al. Effects of niacin-bound chromium and grape seed proanthocyanidins extract on the lipid profile of hypercholesterolemic subjects: a pilot study. J Med. 2000;31(5 and 6):227–246
  99. Grundy SM. Cholesterol management in the era of managed care. Am J Cardiol. 2000;85:3A–9A
  100. McLaren DS. Vitamin deficiency, toxicity and dependency. In:  Berkow R,  Fletcher AJ,  Bondy PK, et al. editor. The Merck Manual. 16th ed.. Rahway, NJ: Merck Research Labs; 1992;
  101. Salvini S, Hennekens CH, Morris JS, et al. Plasma levels of the antioxidant selenium and risk of myocardial infarction among US physicians. Am J Cardiol. 1995;76:1218–1221
  102. Kok FJ, Hofman A, Witteman JCM, et al. Decreased selenium levels in acute myocardial infarction. JAMA. 1989;261:1161–1164
  103. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164(21):2335–2342
  104. Kendler BS. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs. 1997;12:3–23
  105. Salonen JT, Salonen R, Seppanen K, et al. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ. 1991;302:756–760
  106. Kuklinski B, Weissenbacher E, Fahnrich A, et al. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med. 1994;15:S143–S147
  107. Molyneux SL, Young JM, Florkowski CM, et al. Coenzyme q10: is there a clinical role and a case for measurement?. Clin Biochem Rev. 2008;29(2):71–82
  108. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9:273–284
  109. Miguel-Carrasco JL, Mate A, Monserrat MT, et al. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens. 2008;September 11,(epub ahead of print).
  110. Wierzbicki AS. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract. 2008;62(8):1142–1146
  111. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–2619
  112. Kenny D, Warltier DC, Pleuss JA, et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992;70:1347–1352
  113. Kestin M, Clifton P, Belling GB, et al. N-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr. 1990;51:1028–1034
  114. O'Keefe J, Harris W. Omega-3 fatty acids: time for clinical implementation?. Am J Cardiol. 2000;85:1239–1241
  115. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230
  116. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet. 2008;372:1195–1196
  117. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–28
  118. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9597):1090–1098
  119. Rauch B, Schiele R, Schneider S, et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. Cardiovasc Drugs Ther. 2006;20(5):365–375
  120. Siani A, Pagano E, Iacone R, et al. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens. 2000;13:547–551
  121. Candipan RC, Wang B, Buitrago R, et al. Regression or progression (Dependency on vascular nitric oxide). Arteriothromb Vasc Biol. 1996;16:44–50
  122. Drexler H, Zeiher AM, Meinzer K, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 1991;338:1546–1550
  123. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. Circulation. 1996;94:130–134
  124. Quyyumi A, Dakak N, Diodati J, et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997;30:1220–1227
  125. Lerman A, Burnett JC, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123–2128
  126. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101:2160–2164
  127. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87–104
  128. Quyyumi A. Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? (A double-blind comparison of parenteral D- and L-arginine). J Am Coll Cardiol. 1998;32:904–911
  129. Ito T, Kimura Y, Uozumi Y, et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol. 2008;44(5):927–937
  130. Oudit GY, Trivieri MG, Khaper N, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload marine model. Circulation. 2004;109:1877–1885
  131. Safi AM, Stein RA. Role of nutriceutical agents in cardiovascular diseases: an update—Part I. Cardiovasc Rev Rep. 2003;24:382–385
  132. Solerte SB, Fioravanti M, Locatelli E, et al. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. Am J Cardiol. 2008;101(suppl 11A):82E–88E
  133. Kalantar-Zadeh K, Anker SD, Horwich TB, et al. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol. 2008;101(suppl 11A):89E–103E
  134. Aquilani R, Viglio S, Iadarola P, et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol. 2008;101(suppl 11A):104E–110E
  135. Corsetti G, Pasini E, D'Antona G, et al. Morphometric changes induced by amino acid supplementation in skeletal and cardiac muscles of old mice. Am J Cardiol. 2008;101(suppl 11A):26E–34E
  136. Scarabelli TM, Townsend PA, Scarabelli CC, et al. Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol. 2008;101(suppl 11A):63E–68E
  137. Scarabelli TM, Pasini E, Stephanou A, et al. Nutritional supplementation with mixed essential amino acids enhances myocycte survival, preserving mitochondrial functional capacity during ischemia-reperfusion injury. Am J Cardiol. 2004;93(8A):35A–40A
  138. Frishman WH, Sinatra ST, Moizuddin M. The use of herbs for treating cardiovascular disease. Sem Integr Med. 2004;2:23–35
  139. Sinatra ST, Frishman WH, Peterson SJ. Use of alternative medicines in treating cardiovascular disease. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics Manual. 2nd ed.. New York, NY: McGraw Hill; 2004;p. 485–512
  140. Frishman WH, Sinatra ST, Moizuddin M. Herbal approach to cardiac disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 86–106
  141. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135:594–600
  142. Sinatra ST, Frishman WH, Peterson SJ, et al. Use of alternative/complementary medicine in treating cardiovascular disease. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics. 2nd ed.. New York, NY: McGraw Hill; 2003;p. 857–874
  143. Marcus DM, Grollman AP. Botanical medicine—the need for new regulations (sounding board). N Engl J Med. 2002;347:2073–2076
  144. Slifman NR, Obermeyer WR, Musser SM, et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med. 1998;339:806–811
  145. Radford DJ, Gillies AD, Hinds JA, et al. Naturally occurring cardiac glycosides. Med J Aust. 1986;144:540
  146. Dasgupta A, Tso G, Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. J Clin Lab Anal. 2008;22(4):295–301
  147. Clinical Trial: Trial to assess safety of hawthorn and digoxin in CHF. www.clinicaltrials.gov/ct
  148. Clinical Trial: Trial to assess effect of hawthorn in CHF. www.clinicaltrials.gov/ct
  149. Aaronson K. HERB CHF (Hawthorn Extract Randomized Blinded Chronic HF Study) presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America. 2004;September 12-15, Toronto, Canada.
  150. Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail. 2008;10(6):587–593
  151. Jerie P. Milestones of cardiovascular therapy. IV. Reserpine. Cas Lek Cesk. 2007;146(7):573–577
  152. Sutter MC, Wang YX. Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res. 1993;27:1891–1901
  153. Kawashima K, Hayakawa T, Miwa Y, et al. Structure and hypotensive activity relationships of tetrandrine derivatives in stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1990;21:343–347
  154. Ody P. The Complete Medicinal Herbal. New York, NY: Dorling Kindersley; 1993;
  155. Ma G, Ding S, Feng Y, et al. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model. J Cardiovasc Pharmacol. 2007;50(2):201–205
  156. Kuramochi T, Chu J, Suga T. Gou-teng (from Uncaria rhynchophylla Miquel) induced endothelium-dependent and independent relaxations in the isolated rat aorta. Life Sci. 1994;54:2061–2069
  157. Wang L, Li W, Liu Y. Hypotensive effect and toxicology of total alkaloids and veratramine from roots and rhizomes of Veratrum nigrum L. in spontaneously hypertensive rats. Pharmazie. 2008;63(8):606–610
  158. Chang Q, Zuo Z, Harrison F, et al. Hawthorn. J Clin Pharmacol. 2002;42:605–612
  159. Vibes J, Lasserre B, Gleye J, et al. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids. 1994;50:173–175
  160. Shanthi S, Parasakthy K, Deepalakshmi PD, et al. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys. 1994;31:143–146
  161. Nasa Y, Hashizume H, Hoque AN, et al. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung. 1993;43:945–949
  162. Roddewig C, Hensel H. Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crataegus fraction (oligomere procyanidines). [German] Arzneimittelforschung. 1977;27:1407–1410
  163. Baughman KL, Bradley DJ. Hawthorn extract: is it time to turn over a new leaf?. Am J Med. 2003;114:700–701
  164. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med. 2003;114:665–674
  165. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneim Forsch. 1995;45:842–845
  166. Zhang W, Wojta J, Binder BR. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Arterioscler Thromb. 1994;14:1040–1046
  167. Lin SG, Zheng XL, Chen QY, et al. Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum. Chung Kuo Yao Li Hsueh Pao. 1993;14:314–316
  168. Zhang YG, Zhang HG, Zhang GY, et al. Panax Notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin Exp Pharmacol Physiol. 2008;July 9, (epub ahead of print).
  169. Lam FF, Yeung JH, Chan KM, et al. Dihydrotanshinone, a lipophilic component of Salvia Miltiorrhiza (danshen), relaxes rat coronary artery by inhibition of calcium channels. J Ethnopharmacol. 2008;119(2):318–321
  170. Ried K, Frank OR, Stocks NP, et al. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovascular Disord. 2008;8:13
  171. Lau BH. Suppression of LDL oxidation by garlic compounds is a possible mechanism of cardiovascular health benefit. J Nutr. 2006;136(3):765S–768S
  172. Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167(4):325–326
  173. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813–824
  174. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463–468
  175. Silagy C, Neil A. Garlic as a lipid lowering agent—a meta-analysis. J R Coll Physicians Lond. 1994;28:39–45
  176. Clinical Trial: Trial to identify the anti-blood-clotting compounds in garlic. www.clinicaltrials.gov/ct
  177. Tyler VE. Herbs of choice. In:  Tyler VE editors. The Therapeutic Use of Phytomedicinals. New York, NY: Pharmaceutical Product Press; 1994;
  178. Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves thelipid-lowering efficacy. Metabolism. 2008;57(8):1029–1037
  179. Low Dog T. Herbs in cardiovascular diseases (Botanical Medicine in Modern Clinical Practice 8th Annual Course). New York: Columbia University; 2003;June 9-13
  180. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury and arsenic in US- and Indian-manufactured ayurvedic medicines sold via the internet. JAMA. 2008;300:915–923
  181. Clinical Trials (Safety of an herbal treatment for high cholesterol in individuals with statin intolerance). www.clinicaltrials.gov/ct
  182. Clinical Trials (Statin therapy vs. therapeutic lifestyle changes and supplements). www.clinicaltrials.gov/ct
  183. Gardner CD, Taylor-Piliae RE, Kiazand A, et al. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev. 2008;28(4):258–265
  184. Stevermer JJ, Lindbloom EJ. Ginkgo biloba for dementia. J Fam Pract. 1998;46:20
  185. Solomon PR, Adams F, Silver A, et al. Ginkgo for memory enhancement (A randomized controlled trial). JAMA. 2002;288:835–840
  186. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 1998;352:36
  187. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50:1933–1934
  188. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775–1776
  189. Gianni L, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharm. 1998;23:80
  190. Offord EA, Mace K, Ruffieux C, et al. Rosemary components inhibit benzo(a)pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis. 1995;16:2057–2062
  191. Haraguchi H, Saito T, Okamura N, et al. Inhibition of lipid peroxidation and superoxide generation by diterpenoids from Rosmarinus officinalis. Planta Med. 1995;61:333–336
  192. Larrondo JV, Agut M, Calvo-Torras MA. Antimicrobial activity of essences from labiates. Microbios. 1995;82:171–172
  193. al-Hader AA, Hasan ZA, Aqel MB. Hyperglycemic and insulin release inhibiting effects of Rosmarinus officinalis. J Ethnopharmacol. 1994;43:217–221
  194. Tyler VE. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed.. New York, NY: Pharmaceutical Product Press; 1993;
  195. Diehm C, Vollbrecht D, Amendt K, et al. Medical edema protection—clinical benefit in patients with chronic deep vein incompetence: a placebo controlled double blind study. Vasa. 1992;21:188–192
  196. Lang W. Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med. 1977;169:175–187
  197. Berg D. Venous constriction by local administration of ruscus extract. (German) Fortschr Med. 1990;108:473–476
  198. Berg D. Venous tonicity in pregnancy varicose veins. (German) Fortschr Med 110. 1992;67:71
  199. Li YP, Wang YM. Evaluation of tussilagone: a cardiovascular respiratory stimulant isolated from Chinese herbal medicine. Gen Pharmacol. 1988;19:261–263
  200. Flanagan CM, Kaesberg JL, Mitchell ES, et al. Coronary artery aneurysm and thrombosisfollowing chronic ephedra use. Int J Cardiol. 2008;August 19, (epub ahead of print).
  201. Chan TYK, Chan JCN, Tomlinson B, et al. Chinese herbal medicines revisited: the Hong Kong perspective. Lancet. 1993;342:1532–1534
  202. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med. 1996;156:899–903
  203. Frishman WH, Opie LH, Sica DA. Adverse cardiovascular drug interactions and complications. In:  Fuster V,  Alexander RW,  O'Rourke RA, et al. editor. Hurst's The Heart. 11th ed.. New York, NY: McGraw Hill; 2004;p. 2169–2188
  204. Wang Z, Gorski C, Hamman MA, et al. The effects of St. John's Wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317–326
  205. Tannergran C, Engman H, Knutson L, et al. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther. 2004;75:298–309
  206. Mueller SC, Uehleke B, Woehling H, et al. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546–557
  207. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, Echinacea, saw palmetto and kava. Ann Intern Med. 2002;136:42–53
  208. Yuan C-S, Wei G, Dey L, et al. Brief communications: American ginseng reduces warfarin's effect in healthy patients. Ann Intern Med. 2004;141:23–27
  209. Clauson KA, Santamarina ML, Rutledge JC. Clinically relevant safety issues associated with St. John's wort product labels. BMC Complement Altern Med. 2008;8:42
  210. Grattan JG. Mind-body approach to cardiac illness. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 108–126
  211. Reibel DK, Greeson JM, Brainard GC, et al. Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen Hosp Psychiatry. 2001;23:183–192
  212. Teasdale JD, Segal ZV, Williams JM, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000;68:615–623
  213. Paul-Labrador M, Polk D, Dwyer JH, et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med. 2006;166:1218–1224
  214. Schneider RH, Nidich SI, Salerno JW, et al. Lower lipid peroxide levels in practitioners of transcendental meditation program. Psychosom Med. 1998;60:38–41
  215. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to transcendental meditation: a meta-analysis. Am J Hypertens. 2008;21:310–316
  216. Cunningham C, Brown S, Kaski JC. Effects of transcendental meditation on symptoms and electrocardiographic changes in patients with cardiac syndrome. Am J Cardiol. 2000;85:653–655
  217. Patel D, Marmot MG, Terry DJ, et al. Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed). 1985;290:1103–1106
  218. Clinical Trials (Effects of meditation on mechanism of coronary heart disease). www.clinicaltrials.gov/ct
  219. Clinical Trials (Mindfulness based stress reduction for high blood pressure). www.clinicaltrials.gov/ct
  220. Clinical Trials (Improvement in clinical outcomes in heart failure patients with ICDs that practice meditation). www.clinicaltrials.gov/ct
  221. Harmon RL, Myers MA. Prayer and meditation as medical therapies. Phys Med Rehabil Clin North Am. 1999;10:651–662
  222. Al A, Dunkle RE, Peterson C, et al. The role of private prayer in psychological recovery among midlife and aged patients following cardiac surgery. Gerontologist. 1998;38:591–601
  223. Harris WS, Gowda M, Kolb JW, et al. A randomized controlled trial of the effects of remote, intercessory prayer on outcomes in patients admitted to the coronary care unit. Arch Intern Med. 1999;159:2273–2278
  224. Aviles JM, Wheelan SE, Hernke DA, et al. Intercessory prayer and cardiovascular disease progression in a coronary care unit population: a randomized controlled trial. Mayo Clin Proc. 2001;76:1192–1198
  225. Krucoff MW, Crater SW, Green CL, et al. Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: monitoring and actualization of noetic training (MANTRA) feasibility pilot. Am Heart J. 2001;142:760–767
  226. Krucoff MW, Crater SW, Gallup D, et al. Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet. 2005;366:211–217
  227. Trakhtenberg EC. The effects of guided imagery on the immune system: a critical review. Int J Neurosci. 2008;118(6):839–855
  228. Richardson MA, Post-White J, Grimm EA, et al. Coping, life attitudes and immune responses to imagery and group support after breast cancer treatment. Altern Ther Health Med. 1997;3:62–70
  229. Spiegel D, Moore R. Imagery and hypnosis in the treatment of cancer patients. Oncology. 1997;11:1179–1189
  230. Fass AE. Hypnosis for the relief of cardiac symptomatology. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 127–134
  231. Benson H, Frankel FH, Apel R, et al. Treatment of anxiety: a comparison of the usefulness of self-hypnosis and a meditational relaxation technique (An overview). Psychother Psychosom. 1978;30:229–242
  232. DeBenedittis G, Cigada M, Bianchi A, et al. Autonomic changes during hypnosis: a heart rate variability power spectrum analysis as a marker of sympatho-vagal balance. Int J Clin Exp Hypn. 1994;42:140–152
  233. Das S, O'Keefe JH. Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. Curr Hypertens Rep. 2008;10(5):374–381
  234. Blumenthal JA, Babyak M, Wei J, et al. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. Am J Cardiol. 2002;89:164–168
  235. Blumenthal JA, Jiang W, Babyak MA, et al. Stress management and exercise training in cardiac patients with myocardial ischemia. Arch Int Med. 1997;157:2213–2223
  236. Burker EJ, Fredrikson M, Rifai N, et al. Serum lipids, neuroendocrine, and cardiovascular responses to stress in men and women with mild hypertension. BehavMed. 1994;19:155–161
  237. Schneider RH, Staggers F, Alexander CN, et al. A randomized controlled trial of stress reduction for hypertension in older African Americans. Hypertension. 1995;26:820–827
  238. McGrady A. Biofeedback in cardiovascular disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 135–150
  239. Schwartz M, Andrasik F. Biofeedback (A Practitioner's Guide). 3rd ed.. New York, NY: Guilford Press; 2003;
  240. In:  Lehrer P,  Woolfolk RL editor. Principles and Practice of Stress Management. 2nd ed.. New York, NY: Guilford Press; 1993;
  241. Clinical Trials (Hypertension: Prediction of biofeedback success). www.clinicaltrials.gov/ct
  242. Clinical Trials (Impact of a psychological biofeedback-relaxation intervention on clinical, physical and psychological outcomes in patients with heart failure). www.clinicaltrials.gov/ct
  243. Bruscia KE. Defining Music Therapy. In: Gilsum, Pa: Barcelona; 1998;p. 20
  244. Hanser SB, Mandel SE. The effects of music therapy in cardiac healthcare. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 320–330
  245. Logtenberg SJ, Kleefstra N, Houweling ST, et al. Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. J Hypertens. 2007;25:241–246
  246. Hirsch AR. Aromatherapy in cardiac conditions. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 300–319
  247. Stein TR, Oz M. Integrative medicine in cardiothoracic surgery. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 398–414
  248. Sahakian A, Frishman WH. Humor and the cardiovascular system. Altern Therap. 2007;13:56–58
  249. Fry WF. The physiologic effects of humor, mirth and laughter. JAMA. 1992;267:1857–1858
  250. Black DW. Laughter. JAMA. 1984;252:2995–2998
  251. Berk LS, Tan SA, Fry WF, et al. Neuroendocrine and stress hormone changes during mirthful laughter. Am J Med Sci. 1989;298:390–396
  252. LaForge R. Mind-body fitness: encouraging prospects for primary and secondary prevention. J Cardiovasc Nurs. 1997;11:53–65
  253. Raju PS, Prasad KV, Venkata RY, et al. Influence of intensive yoga training on physiological changes in 6 adult women: a case report. J Altern Complement Med. 1997;3:291–295
  254. Cohen D, Townsend RR. Yoga and hypertension. J Clin Hypertens. 2007;9:800–801
  255. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001–2007
  256. Manchanda SC, Narang R, Reddy KS, et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India. 2000;48:687–694
  257. Clinical Trials (The Penn Lifestyle Modification and Blood Pressure Study). www.clinicaltrials.gov/ct
  258. Jahnke R. Qigong and tai chi: traditional Chinese health promotion practices in the prevention and treatment of cardiovascular disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 204–219
  259. Lan C, Chen SY, Wong MK, et al. Tai Chi training for patients with coronary heart disease. Med Sport Sci. 2008;52:182–194
  260. Channer KS, Barrow D, Barrow R, et al. Changes in haemodynamic parameters following Tai Chi Chuan and aerobic exercise in patients recovering from acute myocardial infarction. Postgrad Med J. 1996;72:349–351
  261. Tsai JC, Wang WH, Chan P, et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. J Altern Complement Med. 2003;9:747–754
  262. Lan C, Su TC, Chen SY, et al. Effect of Tai Chi Chuan training on cardiovascular risk factors in dyslipidemic patients. J Altern Complement Med. 2008;14:813–819
  263. Taylor-Piliae RE. Tai Chi as an adjunct to cardiac rehabilitation exercise training. J Cardiopulm Rehabil. 2003;23:90–96
  264. Lan C, Chan SY, Wong MK. The effect of Tai Chi on cardiorespiratory function in patients with coronary artery bypass surgery. Med Sci Sports Exerc. 1999;31:634–638
  265. Yeh GY, Wood MJ, Lorell BH, et al. Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: a randomized controlled trial. Am J Med. 2004;117:541–548
  266. Prasher B, Negi S, Aggarwal S, et al. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. J Transl Med. 2008;6(1):48
  267. Gerson S. Ayurveda: The Ancient Indian Healing Art. 1st ed.. Boston, MA: Elements Books Limited; 1993;(Reprinted 1998).
  268. Mamtani R, Mamtani R. Ayurveda and yoga in cardiovascular diseases. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 168–181
  269. Lad V. An introduction to Ayurveda. Altern Ther. 1995;1:57
  270. Sharma H, Chandola HM, Singh G, et al. Utilization of ayurveda in health care: an approach for prevention, health promotion, and treatment of disease (Part 2—Ayurveda in primary health care). J Altern Complement Med. 2007;13(10):1135–1150
  271. Hole LCN. Heart Qi and the heart of healing: Qigong for the prevention and treatment of cardiac diseases. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 182–203
  272. Pippa L, Manzoli L, Corti I, et al. Functional capacity after traditional Chinese Medicine (Qi Gong) training in patients with chronic atrial fibrillation: a randomized controlled trial. Prev Cardiol. 2007;10:22–25
  273. Hui PN, Wan M, Chan WK, et al. An evaluation of two behavioral rehabilitation programs, qigong versus progressive relaxation, in improving the quality of life in cardiac patients. J Altern Complement Med. 2006;12(4):351–353
  274. Nauman E. Native American medicine and cardiovascular disease. Cardiol Rev. 2007;15:35–41
  275. Ai Gvhdi Waya . Native American healing for the heart. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 220–231
  276. Whitmont RD, Mamtani R. Homeopathy with a special focus on treatment of cardiovascular disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 232–247
  277. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? (Comparative study of placebo-controlled trials of homoeopathy and allopathy). Lancet. 2005;366(9487):726–732
  278. Goldacre B. Benefits and risks of homeopathy. Lancet. 2007;370(9600):1672–1673
  279. Prasad R. Homeopathy booming in India. Lancet. 2007;370(9600):1679–1680
  280. DiGiovanna EL, Marinke DJ, Dowling DJ. Introduction to osteopathic medicine. In:  DiGiovanna EL,  Schiowitz S editor. An Osteopathic Approach to Diagnosis and Treatment. 2nd ed.. New York, NY: Lippincott-Raven; 1997;p. 2–13
  281. Spiegel AJ, Capobianco JD. Osteopathic manipulative medicine in the treatment of hypertension. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 248–258
  282. Pomeranz B. Scientific basis of acupuncture. In:  Stux G,  Pomeranz B editor. Acupuncture Textbook and Atlas. Berlin: Springer-Verlag; 1987;
  283. Ulett GA, Han J, Han S. Traditional and evidence-based acupuncture: history, mechanism, and present status. South Med J. 1998;91:1115–1120
  284. Ernst E. Acupuncture: What does the most reliable evidence tell us?. J Pain Symptom Manage. 2008;September 11, (epub ahead of print).
  285. World Health Organization. A proposed standard international acupuncture nomenclature: report of WHO scientific group. Geneva: World Health Organization; 1991;
  286. Weintraub MI, Mamtani R, Micozzi MS. Complementary and Integrative Medicine in Pain Management. New York, NY: Springer Publishing Co; 2008;
  287. Altman S. Techniques and instrumentation. Probl Vet Med. 1992;4(1):66–87
  288. Schlager A, Offer T, Baldissera I. Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery. Br J Anaesthesia. 1998;81:529–532
  289. In:  Weintraub M editors. Alternative and Complementary Treatment in Neurologic Illness. New York, NY: Churchill; 2001;
  290. Longhurst JC. Central and peripheral neural mechanisms of acupuncture in myocardial ischemia. Intl Congress Series. 2002;1238:79–87(9)
  291. Mamtani R, Frishman WH. Acupuncture in cardiovascular diseases. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 260–273
  292. Williams T, Mueller K, Cornwall MW. Effect of acupuncture-point stimulation on diastolic blood pressure in hypertensive patients: a preliminary study. Phys Ther. 1991;71:523–529
  293. Richter A, Herlitz J, Hjalmarson A. Effect of acupuncture in patients with angina pectoris. Eur Heart J. 1991;12:175–178
  294. Kurono Y, Egawa M, Yano T, et al. The effect of acupuncture on the coronary arteries as evaluated by coronary angiography: a preliminary report. Am J Chin Med. 2002;30:387–396
  295. NIH Consensus Development Conference Statement Online 1997 (Acupuncture). http://odp.od.nih.gov/consensus/cons/107/107_statement.htmlAccessed February 10, 2004.
  296. Longhurst JC. Acupuncture's beneficial effects on the cardiovascular system. Prev Cardiol. 1998;1:21–33
  297. Calenda E, Fleck S. Therapeutic massage and Asian bodywork. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 369–383
  298. Song LZYX, Schwartz GER, Russek LGS. Heart-focused attention and heart-brain synchronization: energetic and physiological mechanisms. Altern Ther. 1998;4(5):44–62
  299. Tiller WA, McCraty R, Atkinson M. Cardiac coherence: a new noninvasive measure of autonomic nervous system order. Altern Ther Health Med. 1996;2(1):52–65
  300. Spence JE, Olson MA. Quantitative research on therapeutic touch: an integrated review of the literature 1985-1995. Scand J Caring Sci. 1997;11:183–190
  301. Heidt P. Effect of therapeutic touch on anxiety level of hospitalized patients. Nurs Res. 1980;30:32–37
  302. Olney CM. The effect of therapeutic back massage in hypertensive patients: a preliminary study. Biol Res Nurs. 2005;7(2):98–105
  303. McNamara ME, Burnham DC, Smith C, et al. The effects of back massage before diagnostic cardiac catheterization. Altern Ther Health Med. 2003;9:50–57
  304. Delaney JP, Leong KS, Watkins A, Brodie D. The short-term effects of myofascial trigger point massage therapy on cardiac autonomic tone in healthy subjects. J Adv Nurs. 2002;37:364–371
  305. Bisson DA. Reflexology. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 331–341
  306. Weintraub MI, Frishman WH. Magnetic biostimulation: energy therapy. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 384–389
  307. Weintraub MI. Magnetotherapy: historical background with a stimulating future. Crit Rev Phys Rehab Med. 2004;16:95–108
  308. Keast M, Adamo K. The Finnish sauna bath and its use in patients with cardiovascular disease. J Cardiopulmon Rehabil. 2000;20:225–230
  309. Hannuksela M, Ellahham S. Benefits and risks of sauna bathing. Am J Med. 2001;110:118–126
  310. Hasan J, Karvonen MJ, Piironen P. Special Review. Part I. Physiological effects of extreme heat as studied in the Finnish “sauna” bath. Am J Phys Med. 1966;45:296–314
  311. Hasan J, Karvonen MJ, Piironen P. Special review. Part II. Physiological effects of extreme heat as studied in the Finnish “sauna” bath. Am J Phys Med. 1967;46:1226–1246
  312. Leppaluoto J, Tuominen M, Vaananen A, et al. Some cardiovascular and metabolic effects of repeated sauna bathing. Acta Physiol Scand. 1986;128:77–81
  313. Nguyen Y, Naseer N, Frishman WH. Sauna as a therapeutic option for cardiovascular disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 342–349
  314. Mussivand T, Alshaer H, Haddad H, et al. Thermal therapy: a viable adjunct in the treatment of heart failure?. Congest Heart Fail. 2008;14(4):180–186
  315. Blum N, Blum A. Beneficial effects of sauna bathing for heart failure patients. Exp Clin Cardol. 2007;12(1):29–32
  316. Diagnostic and therapeutic technology assessment: chelation therapy. JAMA. 1983;250:672
  317. Olszewer E, Carter JP. EDTA chelation therapy: a retrospective study of 2870 patients. J Adv Med. 1989;2:197–211
  318. Clarke NE, Clarke CN, Mosher RF. The “in vivo” dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci. 1955;229:142–149
  319. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997; results of a follow-up national survey. JAMA. 1998;280:1569–1575
  320. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139–160
  321. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Trask Force on Practice Guidelines. J Am Coll Cardiol 33:2092-190 (published erratum 1999;34:314).
  322. Cranton EM. Laguna Hills: American College of Advancement in Medicine; 1989;
  323. Frishman WH, Retter A, Misailidis J, et al. Innovative pharmacologic approaches to the treatment of myocardial ischemia. In:  Frishman WH,  Sonnenblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics. 2nd ed.. New York, NY: McGraw Hill; 2003;p. 655–690
  324. Frishman WH, Wolff AI. Chelation therapy. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies in Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 288–299
  325. Chappell LT. Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?. Altern Med Rev. 2007;12(2):152–158
  326. Mitka M. Chelation therapy trials halted (medical news & perspectives). JAMA. 2008;300:2236
  327. Wolff AI, Frishman WH. Animal-assisted therapy and cardiovascular disease. In:  Frishman WH,  Weintraub MI,  Micozzi M editor. Complementary and Integrative Therapies for Cardiovascular Disease. St. Louis, MO: Elsevier; 2005;p. 362–368
  328. Tyberg A, Frishman WH. Animal-assisted therapy. In:  Weintraub MI,  Mamtani R,  Micozzi MS editor. Complementary and Integrative Medicine in Pain Management. New York, NY: Springer Publishing Co; 2008;p. 115–123
  329. Voith V. Attachment of people to companion animals. Vet Clin North Am Small Anim Pract. 1985;15:289-5.
  330. Marx MB, Stallones TF, Garrity JR, et al. Demographics of pet ownership among US adults 21-64 years of age. Anthrozoos. 1988;2(1):33–37
  331. Francis GM. Loneliness: measuring the abstract. Intl J Nurs Studies. 1976;13:153–160
  332. Delta Society. Standard of practice for animal assisted activities and therapy. Renton, WA: Delta Society; 1996;
  333. Bueno EA, Mamtani R, Frishman WH. Alternative approaches to the medical management of angina pectoris (Acupuncture, electrical nerve stimulation, and spinal cord stimulation). Heart Dis. 2001;3:236–241
  334. Kim MC, Kini K, Sharma SK. Refractory angina pectoris (Mechanism and therapeutic options). J Am Coll Cardiol. 2002;39:923–934
  335. Eliasson T, Augustinsson L-E, Mannheimer C. Spinal cord stimulation in severe angina pectoris—presentation of current studies, indications and clinical experience. Pain. 1996;65:169–179
  336. Ansari S, Chaudhri K, Moutaery K. Neurostimulation for refractory angina pectoris. Acta Neurochir Suppl. 2007;97(Pt. 1):283–288
  337. Marshall DA, Walizer E, Vernalis MN. Optimal healing environments for chronic cardiovascular disease. J Alt Comp Med. 2004;10(suppl 1):S147–S155

PII: S0011-5029(08)00159-4

doi: 10.1016/j.disamonth.2008.12.002

Disease-A-Month
Volume 55, Issue 3 , Pages 121-192 , March 2009

Article Tools

* Image Usage & Resolution